Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IM21 CAR-T Cells (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 13 Dec 2022 Results (As of July 22, 2022, n=16 )presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 08 Sep 2020 New trial record